Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18434394 | 1.00 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL392021 | 1.00 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL20734969 | 0.94 | MTOR (0.88) | MTORAKT1 | |
| SCHEMBL394905 | 0.91 | MTOR (0.83) | MTORAKT1 | |
| SCHEMBL394906 | 0.91 | MTOR (0.83) | MTORAKT1 | |
| SCHEMBL18434225 | 0.91 | MTOR (0.83) | MTORAKT1 | |
| SCHEMBL10224930 | 0.91 | MTOR (1.00) | MTORAKT1 | |
| SCHEMBL2907590 | 0.90 | MTOR (1.00) | MTOR | |
| SCHEMBL10225071 | 0.90 | MTOR (1.00) | MTOR | |
| SCHEMBL18434090 | 0.90 | MTOR (1.00) | MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2018-07-31 | — | — | US | disclosed |
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-9717736-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| EP-2057156-B1 | 2-METHYLMORPHOLINE PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | KUDOS PHARM LTD (GB) | 2017-02-01 | — | — | EP | disclosed |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARM LTD (GB) | 2016-03-10 | — | — | US | disclosed |
| US-9102670-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-20140135315-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8435985-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MENEAR KEITH (GB) | 2013-05-07 | — | — | US | disclosed |
| US-20120142673-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-8101602-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | Kudos Pharmaceuticals, Ltd. (GB) | 2012-01-24 | — | — | US | disclosed |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2011-05-26 | — | — | US | disclosed |
| US-7902189-B2 | antitumor agent, anticarcinogenic agents; 7-Chloro-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine; inhibitors of mTOR kinase | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080081809-A1 | Novel Compounds | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281637-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
| US-10034884-B2 | Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
| US-20120142673-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
| US-20160067258-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
| US-20110124638-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 221/4885 |
| US-20080081809-A1 | Novel Compounds | SLC10A1, ABCB11, PKD1 | MTOR 203/4885AKT1 1066/4885 |
| US-20140135315-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885AKT1 213/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | MTOR 24/4885AKT1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.